- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03372655
Prognostic Factors Affecting Duchenne Muscular Dystrophy
December 10, 2017 updated by: Nehal Refaat Mohammed, Assiut University
Prognstic Factors Affecting Duchenne Muscular Dystrophy
Determination of prognostic factors affecting ambulation of duchenne muscular dystrophy
Study Overview
Status
Unknown
Conditions
Detailed Description
Duchenne muscular dystrophy is the most common herditary muscular disease , it lead to loss of ambulation in early teenageers .
It lead to early death at the mean age of 19 years
Study Type
Observational
Enrollment (Anticipated)
82
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
Male
Sampling Method
Non-Probability Sample
Study Population
Male patient diagnosed as duchenne muscular dystrophy by typical clinical picture&shooting serum CPK level & EMG study or biopsy
Description
Inclusion Criteria:
- any male pt diagnosed as duchenne muscular dystrophy by typical clinical picture &shooting serum CPK level &EMG study or biopsy & age 10 to 18yrs old
Exclusion Criteria:
- female patient ' age below 10 yrs old or above 18 yrs old .patient with autoimmune disease or malignancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ten meter walking test
Time Frame: 2018 - 2019
|
Questionnaire
|
2018 - 2019
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Muscle strenght
Time Frame: 2018- 2019
|
Questionnaire
|
2018- 2019
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 1, 2018
Primary Completion (Anticipated)
January 1, 2019
Study Completion (Anticipated)
March 1, 2019
Study Registration Dates
First Submitted
December 6, 2017
First Submitted That Met QC Criteria
December 10, 2017
First Posted (Actual)
December 14, 2017
Study Record Updates
Last Update Posted (Actual)
December 14, 2017
Last Update Submitted That Met QC Criteria
December 10, 2017
Last Verified
December 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PFADMD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Medical University of GdanskRecruitingDuchenne Muscular Dystrophy (DMD)Poland
-
ItalfarmacoCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
Santhera PharmaceuticalsTerminatedDuchenne Muscular Dystrophy (DMD)United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Hospital RudolfstiftungOesterreichische MuskelforschungCompletedCarrier of Duchenne Muscular DystrophyAustria
-
General Hospital of Chinese Armed Police ForcesUnknownDuchenne Muscular Dystrophy (DMD)China
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
Peking Union Medical College HospitalNot yet recruitingDuchenne Muscular Dystrophy (DMD)
-
University of FloridaU.S. Army Medical Research and Development CommandRecruitingDuchenne Muscular Dystrophy (DMD)United States